Biosynthesis of Pyrrolo[1,4]benzodiazepines, potent antitumor antibiotics

吡咯并[1,4]苯二氮卓类药物的生物合成,强效抗肿瘤抗生素

基本信息

  • 批准号:
    8037037
  • 负责人:
  • 金额:
    $ 23.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-05-01 至 2013-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Secondary metabolites are usually produced by an organism as part of a defense mechanism or to facilitate reproduction. The chemical diversity of secondary metabolites mirrors the variety of enzymatic reactions present in the biosynthetic pathways. Therefore, these pathways are a constant and rich source of exciting novel transformations and unprecedented enzymes. In addition, the genetic and enzymatic knowledge acquired by elucidating the biosynthetic pathways can be exploited for the production of chemically varied secondary metabolites. Pyrrolo[1,4]benzodiazepines, a class of potent antitumor antibiotics found in actinomycetes, are sequence selective DNA alkylating agents. Phase 1 human clinical trials of SJG-136 for the treatment of metastatic or unresectable solid tumors were started in 2004. Microbiology, molecular biology and enzymological techniques will be used in this proposal to elucidate the biochemistry underlying pyrrolo[1,4]benzodiapines' production. Specifically, we propose to 1) identify the biosynthetic gene clusters for tomaymycin and sibiromycin, 2) produce novel glycosylated PBDs and PBD dimers, and 3) characterize the unique enzymatic transformations present in the biosynthetic pathway. PUBLIC HEALTH RELEVANCE Pyrrolobenzodiazepines (PBDs) are compounds naturally produced by bacteria with potent antitumor properties. PBDs' remarkable broad spectrum of activities and effectiveness against a wide variety of cancers encourages the development of new PBDs. For instance, SJG-136 is currently in phase I clinical trials against metastatic and unresectable solid tumors. We are proposing to study how nature carries out the synthesis of these compounds. The genetic and enzymological knowledge so obtained can then be used for production of new analogs of these compounds. Examples of such application are discussed in this proposal.
描述(由申请人提供):次生代谢物通常由生物体产生,作为防御机制的一部分或促进繁殖。次生代谢物的化学多样性反映了生物合成途径中存在的酶促反应的多样性。因此,这些途径是令人兴奋的新转化和前所未有的酶的持续和丰富的来源。此外,通过阐明生物合成途径获得的遗传和酶学知识可以用于化学变化的次生代谢物的生产。Pyrrolo[1,4]苯二氮卓类药物是一类发现于放线菌中的有效抗肿瘤抗生素,是序列选择性DNA烷基化剂。SJG-136用于治疗转移性或不可切除实体瘤的一期人体临床试验于2004年开始。本文将利用微生物学、分子生物学和酶学技术来阐明吡咯[1,4]苯二氮生成的生物化学基础。具体来说,我们建议1)鉴定托马霉素和西比霉素的生物合成基因簇,2)生产新的糖基化PBD和PBD二聚体,以及3)表征生物合成途径中存在的独特酶转化。公共

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

STEVEN E ROKITA其他文献

STEVEN E ROKITA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('STEVEN E ROKITA', 18)}}的其他基金

The Chemistry-Biology Interface Program at Johns Hopkins University
约翰·霍普金斯大学化学-生物界面项目
  • 批准号:
    10627441
  • 财政年份:
    2023
  • 资助金额:
    $ 23.46万
  • 项目类别:
Switching Between One and Two Electron Mechanisms in the Nitroreductase Superfamily
硝基还原酶超家族中的一个和两个电子机制之间的切换
  • 批准号:
    10090611
  • 财政年份:
    2019
  • 资助金额:
    $ 23.46万
  • 项目类别:
The Role of a Dehalogenase in Drosophila Spermatogenesis
脱卤酶在果蝇精子发生中的作用
  • 批准号:
    8952629
  • 财政年份:
    2015
  • 资助金额:
    $ 23.46万
  • 项目类别:
Reductive Dehalogenation in Mammals by Iodotyrosine Deiodinase
碘酪氨酸脱碘酶在哺乳动物中的还原脱卤作用
  • 批准号:
    8503704
  • 财政年份:
    2009
  • 资助金额:
    $ 23.46万
  • 项目类别:
Reductive Dehalogenation in Mammals by Iodotyrosine Deiodinase
碘酪氨酸脱碘酶在哺乳动物中的还原脱卤作用
  • 批准号:
    8499664
  • 财政年份:
    2009
  • 资助金额:
    $ 23.46万
  • 项目类别:
Reductive Dehalogenation in Mammals by Iodotyrosine Deiodinase
碘酪氨酸脱碘酶在哺乳动物中的还原脱卤作用
  • 批准号:
    8064636
  • 财政年份:
    2009
  • 资助金额:
    $ 23.46万
  • 项目类别:
Biosynthesis of Pyrrolo[1,4]benzodiazepines, potent antitumor antibiotics
吡咯并[1,4]苯二氮卓类药物的生物合成,强效抗肿瘤抗生素
  • 批准号:
    7930272
  • 财政年份:
    2009
  • 资助金额:
    $ 23.46万
  • 项目类别:
Reductive Dehalogenation in Mammals by Iodotyrosine Deiodinase
碘酪氨酸脱碘酶在哺乳动物中的还原脱卤作用
  • 批准号:
    7698635
  • 财政年份:
    2009
  • 资助金额:
    $ 23.46万
  • 项目类别:
Reductive Dehalogenation in Mammals by Iodotyrosine Deiodinase
碘酪氨酸脱碘酶在哺乳动物中的还原脱卤作用
  • 批准号:
    7871329
  • 财政年份:
    2009
  • 资助金额:
    $ 23.46万
  • 项目类别:
The Chemistry-Biology Interface Program at Johns Hopkins University
约翰·霍普金斯大学化学-生物界面项目
  • 批准号:
    10202632
  • 财政年份:
    2008
  • 资助金额:
    $ 23.46万
  • 项目类别:

相似海外基金

Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
  • 批准号:
    10374792
  • 财政年份:
    2021
  • 资助金额:
    $ 23.46万
  • 项目类别:
Elucidation and prevention of the mechanism of hepatic sinusoidal obstruction syndrome (SOS) induced by DNA alkylating agents
DNA烷化剂诱发肝窦阻塞综合征(SOS)机制的阐明和预防
  • 批准号:
    21K15255
  • 财政年份:
    2021
  • 资助金额:
    $ 23.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Differential resistance mechanisms to monofunctional vs bifunctional alkylating agents in glioma
神经胶质瘤对单功能烷化剂与双功能烷化剂的不同耐药机制
  • 批准号:
    10570900
  • 财政年份:
    2021
  • 资助金额:
    $ 23.46万
  • 项目类别:
Development of individualized therapy by elucidation of molecular mechanisms for hypermutation phenotype induced by treatment with alkylating agents in glioma
通过阐明神经胶质瘤中烷化剂治疗诱导的超突变表型的分子机制来开发个体化治疗
  • 批准号:
    18K09004
  • 财政年份:
    2018
  • 资助金额:
    $ 23.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Reversing intrinsic cancer cell resistance to alkylating agents by histone deacetylase inhibition
通过组蛋白脱乙酰酶抑制逆转癌细胞对烷化剂的内在耐药性
  • 批准号:
    214657440
  • 财政年份:
    2012
  • 资助金额:
    $ 23.46万
  • 项目类别:
    Research Grants
Rerouting alkylating agents to the mitochondria for cancer therapy
将烷化剂重新路由至线粒体用于癌症治疗
  • 批准号:
    247842
  • 财政年份:
    2011
  • 资助金额:
    $ 23.46万
  • 项目类别:
    Studentship Programs
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8105413
  • 财政年份:
    2010
  • 资助金额:
    $ 23.46万
  • 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8271313
  • 财政年份:
    2010
  • 资助金额:
    $ 23.46万
  • 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8730259
  • 财政年份:
    2010
  • 资助金额:
    $ 23.46万
  • 项目类别:
Novel approaches to enhance tumor cell cytotoxicity of alkylating agents
增强烷化剂肿瘤细胞细胞毒性的新方法
  • 批准号:
    8676463
  • 财政年份:
    2010
  • 资助金额:
    $ 23.46万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了